# A Multipronged Interrogation of Large-Scale Omics Data to Reveal COVID-19 Pathways

> **NIH NIH RF1** · WASHINGTON UNIVERSITY · 2020 · $650,002

## Abstract

The COVID-19 global pandemic has led to more than 470,000 deaths. This disease is especially perilous
for the elderly - 80% of deaths in the US have been individuals over the age of 65, and the social isolation created
by lockdowns have increased risks of serious physical and mental health issues.
 COVID-19 is a heterogeneous disease exhibiting a broad spectrum of symptoms, ranging from mild (e.g.
loss of smell, dry cough) to critical (e.g. cytokine storm, renal failure, cardiovascular damage, respiratory failure,
lethal blood clotting, neurological disorders). This clinical heterogeneity demands a precision medicine approach
that elucidates distinct pathways underlying the disease, develops treatments for each pathway, and defines
biomarker patterns to diagnose patients for classification within the subsets. A key benefit of precision medicine
is that drugs may be repurposed or may already exist to treat specific subsets of infected individuals. For
example, one critical outcome for COVID-19 infection is the onset of a cytokine storm, in which the body's
immune system gets caught in a positive feedback loop, leading to shock and rapid failure of multiple organs.
There are existing drugs for treating cytokine storm syndrome, but practitioners have no clear guidelines if such
treatments are beneficial or destructive. If the individual is not in a hyperinflammatory state, the administration
of these drugs could cripple their immune response, leading to increased viral load. Plasma biomarker patterns
of proteins and metabolites hold potential to identify impending cytokine storms and other lethal outcomes.
 To advance precision medicine for COVID-19 treatment, this work will generate large-scale omics data
and evaluate levels of proteins and metabolites for plasma drawn from 350 COVID-19 positive cases and 750
normal controls. These data will be immediately released to the research community. Our research team will
take a concerted multipronged approach for analyzing these data using diverse complementary techniques. Our
labs' research focuses on the discovery of combinations of genes and proteins expressing synchronously and
the associations of these combinations with traits of interest, as well as endophenotype discovery. In addition to
thorough single analyte analyses, this research will employ three computational strategies to reveal combinations
of factors defining patterns: 1) network modeling, 2) explainable-AI systems biology, and 3) linear programming.
These intensive analyses will require significant computational resources and we will utilize Summit at Oak Ridge
National Laboratory, one of the most powerful supercomputers in the world, for these tasks.
 The comprehensive protein and metabolite profiles, based on a large cohort of COVID-19 cases and
normal controls, along with our rigorous interrogation of these data for complex biomarker patterns indicative of
patient outcomes, hold unprecedented potential to drive solid advances in preci...

## Key facts

- **NIH application ID:** 10202278
- **Project number:** 3RF1AG053303-01S2
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Sharlee Climer
- **Activity code:** RF1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $650,002
- **Award type:** 3
- **Project period:** 2016-09-15 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10202278

## Citation

> US National Institutes of Health, RePORTER application 10202278, A Multipronged Interrogation of Large-Scale Omics Data to Reveal COVID-19 Pathways (3RF1AG053303-01S2). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10202278. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*